Last reviewed · How we verify
NCT02471170
Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
trial in Pancreatic Diseases in 100 participants. Enrolling by invitation.
1 January 2035
Quick facts
| Lead sponsor | Abramson Cancer Center at Penn Medicine |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 10 September 2015 |
| Primary completion | 1 January 2035 |
| Estimated completion | 1 January 2035 |
| Sites | 1 location across United States |
Conditions studied
- Pancreatic Diseases — all drugs for Pancreatic Diseases →
Sponsor
Abramson Cancer Center at Penn Medicine — full company profile →
Who can join
18 and older, any sex, with Pancreatic Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to collect blood samples to detect potential markers of pancreatic cancer in the blood and link these findings to medical and health information. Information from this study may help to provide insight into the detection of pancreas cancer in the blood before it can be found by other methods or provide a method of monitoring the status of pancreatic cancer throughout a treatment course. Another purpose of this study is to collect blood to create a biobank.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR).
Krusen BM, Gimotty PA, Donahue G, Till JE, et al · · 2026 · PMID 41593855 · DOI 10.1158/1078-0432.ccr-25-3297 -
Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma.
Till JE, Gal-Rosenberg O, Giliberto SG, Seewald NJ, et al · · 2026 · PMID 41549760 · DOI 10.1002/ctm2.70573
Verify or expand the search:
- PubMed search for NCT02471170
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Diseases
Currently open trials in the same condition.
- NCT06861010 — Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatograp · Phase 3 · recruiting
- NCT06790134 — Validation of an AI-Assisted Pancreatic EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Tri · NA · recruiting
- NCT07030348 — Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study · recruiting
- NCT06041009 — Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations · recruiting
- NCT04493632 — OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry. · recruiting
Other Abramson Cancer Center at Penn Medicine trials
Trials by the same sponsor.
- NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
- NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
- NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02471170 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02471170.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing